Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males, between 18 and 55 years of age, inclusive~* Body Mass Index range 18.0 to 30.0 kg/m2, inclusive~* Have NAT2 slow or rapid acetylator genotype~* In good health as determined by the investigator~* Negative test for selected drugs of abuse at screening~* Negative screens for Hepatitis B, Hepatitis C and HIV~* Sterile or agrees to use an approved method of contraception from Check-in until 45 days following Clinic Discharge~* Able to comprehend and willing to sign an Informed Consent Form~* Have 1 to 2 bowel movements per day~Exclusion Criteria:~* Significant history or clinical manifestation of any significant metabolic, allergic, skin, liver, kidney, blood, heart or blood vessel, digestive system, brain or psychiatric disorder~* History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance~* History of stomach or intestinal surgery or resection~* History or presence of an abnormal ECG,~* History of clinically significant alcohol or drug use within 1 year prior to Check-in~* Participation in more than 1 other radiolabeled investigational study drug trial within 12 months prior to Check-in~* Exposure to significant radiation within 12 months prior to Check-in -Use of any tobacco- or nicotine-containing within 6 months prior to Check- in~* Use of any drugs which may interact with the study drug within 30 days prior to Check-in~* Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 30 days prior to Check-in~* Use of any prescription medications/products within 14 days prior to Check in~* Use of any over-the-counter, non-prescription drugs within 7 days prior to Check-in~* Use of grapefruit or grapefruit-containing foods or beverages within 7 days prior to Check-in~* Use of alcohol- or caffeine-containing foods or beverages within 72 hours prior to Check-in~* Donation of blood from 30 days prior to Screening through Study Completion, inclusive, or of plasma from 2 weeks prior to Screening through Study Completion~* Receipt of blood products within 2 months prior to Check-in~* Any acute or chronic condition that would limit the subject's ability to complete and/or participate in this clinical study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Slow and rapid N-acetyl transferase genotypes (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).